Response to Patoulias et al. letter regarding article “Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial”

Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › fagfællebedømt